Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Umbilical Cord Blood-Derived Mesenchymal Stem Cells for Long-Term Cytopenia After CAR-T Therapy
NCT07212335Phase 1Recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Oct 2025
- Primary completion
- Sep 2027
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Promostem in hematologic toxicity (HT), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: Treatment-Related Adverse Events at 24 weeks. Started Oct 2025; status: recruiting.
02
Drugs
Promostem
03
Conditions
hematologic toxicity (HT)
Beyond the preview
Go deeper on NCT07212335.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07212335.